Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
复制标题
伊马替尼治疗后，单核细胞中GPX-1抗氧化剂硒酶的活性变化。
DOI：
10.1016/j.leukres.2011.01.007
复制
发表时间：
2011-06
影响因子：
2.7
通讯作者：
Diamond AM
中科院分区：
文献类型：
--
作者：
Terry EN;Gann PH;Molokie R;Deininger M;Diamond AM
伊马替尼抑制ABL酪氨酸激酶，并有效治疗慢性粒细胞白血病（CML）。ABL激活GPx-1，一种与保护免受氧化DNA损伤和疾病相关的酶。在伊马替尼治疗前后从患者获得的单核细胞组成的样品对中评估酶活性。从未接受伊马替尼治疗的患者中获得的对照样本集在几个月的时间间隔内显示GPx活性几乎没有变化。从接受伊马替尼的患者中获得的7个样本集中有5个显示GPx活性变化大于30%。一个样本下降了42%，而其他4个样本则上升了33%至208%。活动增加最多的患者是女性，GPx活性的基线水平最低。GPx活性的变化可能影响CML患者的临床结局。
Imatinib inhibits the ABL tyrosine kinase and is effective for the treatment of chronic myeloid leukemia (CML). ABL activates GPx-1, an enzyme associated with protection against oxidative DNA damage and disease. Enzyme activity was assessed in sample pairs consisting of mononuclear cells obtained from patients before and after imatinib therapy. Control sample sets obtained from patients not receiving imatinib showed little change in GPx activity over a several month interval. Five of 7 sample sets obtained from imatinib-receiving patients showed changes in GPx activity greater than 30%. One sample decreased 42% while 4 others increased 33% to 208%. Patients with the largest increase in activity were female and had the lowest baseline levels of GPx activity. Changes in GPx activity may influence the clinical outcome of patients being treated for CML.
登录
查看更多内容
影响因子：
11.2
作者：
Zhuo, Pin;Goldberg, Marci;Diamond, Alan M.
通讯作者：
Diamond, Alan M.
影响因子：
3
作者：
Zhuo, Pin;Diamond, Alan M.
通讯作者：
Diamond, Alan M.
影响因子：
64.5
作者：
HOCKENBERY, DM;OLTVAI, ZN;KORSMEYER, SJ
通讯作者：
KORSMEYER, SJ
影响因子：
4.8
作者：
Cao, C;Leng, YM;Kufe, D
通讯作者：
Kufe, D
DOI：
10.1073/pnas.0308096101
发表时间：
2004-06-15
影响因子：
11.1
作者：
McClung, JP;Roneker, CA;Lei, XG
通讯作者：
Lei, XG